Paper - WANFANG MED ONLINE

You Position: Home > Paper

PARP抑制剂在卵巢上皮性癌分子靶向治疗中的研究进展

( views:378, downloads:596 )

Author:: No author available

Journal Title:: Chinese Journal of Obstetrics and Gynecology

Issue:: 6

DOI:: 10.3760/cma.j.issn.0529-567x.2015.06.015

Key Word:: No keyword available

Abstract：卵巢上皮性癌（卵巢癌）是目前病死率最高的妇科恶性肿瘤。预期美国2014年新增卵巢癌患者21980例，死亡14270例，其病死率明显高于子宫颈癌和子宫内膜癌[1]。其中，约70%的卵巢癌死亡患者为晚期高级别卵巢浆液性癌（high-grade serous ovarian cancer, HGS-OvCa），尽管临床上已广泛开展卵巢癌的规范化治疗，包括肿瘤细胞减灭术以及术后辅以铂类药物为基础的联合化疗，但大多数卵巢癌患者最终死于肿瘤复发和耐药。

Reference

[1]Aly, A.,Ganesan, S..BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability[J].2011,3(1).
[2].BRCA1 and BRCA2: different roles in a common pathway of genome protection.[J].2011,12(1).
[3].Integrated genomic analyses of ovarian carcinoma[J].2011,474(Jun.30 TN.7353).
[4]Siegel,R.,Ma,J.,Zou,Z.,etc.Cancer statistics, 2014[J].2014,64(1).
[5]Ledermann,J.,Harter,P.,Gourley,C.,etc.Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer[J].2012,366(15).
[6]Carmichael J,Hirte H,Tischkowitz M,etc.Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.[J].2011,12(9).
[7].ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome.[J].2009,113(4).
[8]Giaccone,G.,Rajan,A.,Carter,C.A.,etc.A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors[J].2012,18(8).
[9]Nuala,McCabe.Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.[J].2006,66.
[10]Chen AP,Weil MK.PARP inhibitor treatment in ovarian and breast cancer.[J].2011,35(1).
[11]Boss DS,Fong PC,Yap TA.Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.[J].2009,361(2).
[12]Liu,J.F.,Tolaney,S.M.,Birrer,M.,etc.A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer[J].2013,49(14).
[13]Matulonis,U.,Safra,T.,Bell-McGuinn,K.M.,etc.Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer[J].2012,30(4).
[14]Lord,C.J.,Ashworth,A..Mechanisms of resistance to therapies targeting BRCA-mutant cancers[J].2013,19(11).
[15]Berry DA,Broglio KR.Detecting an overall survival benefit that is derived from progression-free survival.[J].2009,101(23).
[16]Tuya, Pal,Jenny, Permuth-Wey,Judith A, Betts,etc.BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.[J].2005,104(12).
[17]Campbell,J.,Ashworth,A.,Lord,C.J.,etc.Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor[J].2013,229(3).
[18]Gourley C,Messiou C,A'Hern R,etc.Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.[J].2010,28(15).
[19]J-M Lee,J A Ledermann,E C Kohn.PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.[J].2014,25(1).
[20]Bernstein H,Garewal H,Bernstein C,etc.DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis.[J].2002,511(2).
[21]Audeh MW,Weitzel JN,Carmichael J,etc.Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.[J].2010,376(9737).